Published in Cancer Weekly, May 26th, 1997
Angiogenesis is critical to the growth of solid tumors and the development of metastasis. Interference with the process of tumor-induced angiogenesis has the potential to be an effective therapy for both primary and metastatic cancers. Currently, about nine angiogenic agents are being evaluated in clinical trials for the treatment of several angiogenesis-dependent diseases.
To develop additional angiogenesis inhibitors for cancer therapy, James W. Fett and colleagues from the Harvard Medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.